TAK-438 Enters into Phase III Clinical Trials in Japan for the Treatment of Acid-related Diseases
Takeda Pharmaceutical Company Limited announced that TAK-438 has entered into Phase III clinical trials in Japan for the treatment of patients with acid-related diseases such as reflux esophagitis.
TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pump). It has a different mechanism of action from proton pump inhibitors (“PPIs”).
TAK-438 is anticipated to have, in clinical use, a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs. The Phase III clinical trials in Japan are multi-centric, and designed to evaluate the safety and efficacy of TAK-438 for diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.
“There are still many patients with acid-related diseases who have severe conditions, or not responsive to PPI therapy,” said Nancy Joseph-Ridge, M.D., Corporate Officer and General Manager, Pharmaceutical Development Division of Takeda. “Leveraging our extensive experience in the area of gastroenterology, we will efficiently conduct the development activities of TAK-438 so that we can offer another potential new treatment option to these patients as quickly as possible.”
Other news from the department research and development
